Granules India net profit rises 39% to ₹182 cr on higher revenue
The Hindu

Revenue crosses ₹1,500 crore despite higher input and logistics costs driven
by West Asia tensions, expect cost pressures to persist, says CMD Chigurupati
The Hindu

Revenue crosses ₹1,500 crore despite higher input and logistics costs driven
by West Asia tensions, expect cost pressures to persist, says CMD Chigurupati
EconomyThe Hindu
The strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
EconomyThe Hindu
Along with their results, Petronet LNG also declared a dividend of ₹7 per equity share
MarketsCNBC-TV18
NCL Industries reported a Q2 FY27 net profit of ₹20 crore with revenue rising to ₹386 crore, while EBITDA declined.
EconomyLiveMint
The company reported an almost 59% jump in consolidated net profit to ₹7,532 crore in Q2, but a 39% rise in input costs during the quarter threatens to squeeze near-term margins.
MarketsCNBC-TV18
Shanika Capital highlights Zydus Lifesciences and Granules India as strong pharmaceutical growth prospects for the upcoming years.
MarketsCNBC-TV18
Relaxo Footwears reported a 2.8% year-on-year rise in Q2 FY27 net profit to ₹37 crore, while revenue increased 11.6% to ₹701.6 crore. For H1 FY27, revenue grew 9.6% to ₹1,407 crore and EBITDA rose 7.1% to ₹193 crore, with a margin of 13.8%.
MarketsEconomic Times
Gland Pharma shares rose nearly 4% after the company reported a 58% increase in Q2 net profit and a 23% rise in revenue.
EconomyNDTV
Revenue from operations for the period under review was at Rs 555 crore, up 3.4 per cent from Rs 537 crore in the July-September period of FY26, the company said.
Several outlets reported this. AI can compare where they agree and differ.